Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. (AVIR) priced its initial public offering on Oct 30, 2020 at $24.00 per share, within its $22.00–$24.00 range, raising $300M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.94B. J.P. Morgan was lead-left underwriter, joined by Morgan Stanley, Evercore ISI and William Blair. Latham & Watkins advised the company and Davis Polk advised the underwriters.

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing antiviral therapeutics for life-threatening viral infections. Its purine nucleotide prodrug platform produces oral candidates targeting single-stranded RNA viruses, including SARS-CoV-2, hepatitis C virus, dengue virus and respiratory syncytial virus.

Status

IPO

Ticker

AVIR

Exchange

Nasdaq Global Select

Priced

Oct 30, 2020

IPO price

$24.00

Price range

$22.00–$24.00

Raised

$300M

Market cap at IPO price

$1.94B

First filed

Oct 9, 2020

Underwriters

J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair

Company counsel

Latham & Watkins

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.